Onconetix Seeks Shareholder Approval for Another Reverse Stock Split to Maintain Nasdaq Listing
ONCO sits 20% above its 52-week low of $1.37 on light trading volume (0.1× avg).
Summary
Onconetix, Inc. is seeking stockholder approval for a reverse stock split, with a ratio between 1-for-2 and 1-for-50, to maintain its Nasdaq listing amidst ongoing compliance challenges and a mandatory panel monitor.
Key Events · Corporate Governance and Compliance · ONCO
-
Proposal for Reverse Stock Split Authority
Stockholders will vote on granting the Board authority to implement a reverse stock split at a ratio between 1-for-2 and 1-for-50.
-
Nasdaq Listing Compliance
The primary reason for the proposed split is to maintain compliance with Nasdaq's minimum bid price rule, which is crucial for the company's market presence.
-
Recent Reverse Split and Panel Monitor
The company previously executed a 1-for-85 reverse stock split in June 2025 and is currently under a mandatory Nasdaq panel monitor until July 2026, which removes the standard grace period for future bid price non-compliance.
-
Risks of Delisting
Failure to maintain Nasdaq listing could lead to trading on over-the-counter markets, significantly reducing liquidity, investor interest, and the company's ability to raise capital.
Analysis · ONCO · Life Sciences
Onconetix is proposing a reverse stock split to address potential future non-compliance with Nasdaq's minimum bid price rule. This action follows a previous 1-for-85 reverse split in June 2025 and the company's current status under a mandatory Nasdaq panel monitor until July 2026. The monitor means any future bid price non-compliance will result in an immediate delisting determination without the standard grace period. The repeated need for reverse splits highlights significant challenges in maintaining a sustainable stock price and Nasdaq listing, which is critical for a micro-cap company's access to capital and market visibility. This proactive measure underscores the precariousness of its listing status and the underlying operational or financial issues preventing organic price appreciation.
At the time of this filing, ONCO was trading at $1.64 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $2.6M. The 52-week trading range was $1.37 to $179.35. This filing was assessed with negative market sentiment and an importance score of 8 out of 10.